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Abstract
Background: MUC4 is a high molecular weight membrane protein that is overexpressed in pancreatic cancer (PC)
and is associated with the development and progression of this disease. However, the exact mechanisms through
which MUC4 domains promote these biological processes have rarely been studied, partly because of its high
molecular weight, difficulty to overexpress it. Here, we use MUC4/Y, one of the MUC4 transcript variants, as a model
molecule to investigate the AMOP-domain of MUC4(MUC/Y).
Methods: We used cell proliferation, migration, invasion and tube formation assays in vitro to explore the abilities
of AMOP domain in PC. In vivo, the matrigel plug assay, orthotopic implantation and Kaplan-Meier survival curves
were used to check the results we observed in vitro. Finally, we discovered the underlying mechanism through
western blot and immunofluorescence.
Results: We found that MUC4/Y overexpression could enhance the angiogenic and metastatic properties of PC
cells, both in vitro and in vivo. However, the deletion of AMOP domain could cutback these phenomena.
Additionally, Kaplan-Meier survival curves showed that mice injected with MUC4/Y overexpressed cells had shorter
survival time, compared with empty-vector-transfected cells (MUC4/Y-EV), or cells expressing MUC4/Y without the
AMOP domain (MUC4/Y-AMOP△). Our data also showed that overexpression of MUC4/Y could activate NOTCH3
signaling, increasing the expression of downstream genes: VEGF-A, MMP-9 and ANG-2.
Conclusions: The AMOP domain had an important role in MUC4/Y (MUC4)-mediated tumour angiogenesis and
metastasis of PC cells; and the NOTCH3 signaling was involved. These findings provided new insights into PC
therapies. Our study also supplies a new method to study other high molecular membrane proteins.
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Background
Pancreatic Cancer (PC) is the fourth leading cause of death
due to cancer worldwide [1]. The incidence and number of
deaths caused by PC have been gradually increasing, even
as the incidence and mortality of other common cancers
have been declining. Surgical resection remains the only
chance for cure, but approximately 80–85 % of patients
present with advanced un-resectable state at the time of
diagnosis. Unfortunately, PC responds poorly to most che-
motherapeutic agents; thus, the 5 year survival rate is only
approximately 4 % [2]. Hence, the biological mechanisms
that contribute to the development and progression of PC
need to be investigated.
MUC4, a large membrane-anchored glycoprotein, is
aberrantly expressed in various types of cancers and in-
flammatory diseases. Its expression is undetectable in
normal pancreatic tissue and chronic pancreatitis, but it
is highly expressed in pancreatic intraepithelial neoplasia
and PC [3]. We and other researchers have reported that
MUC4 is involved in various biological properties of PC
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cells, including growth, apoptosis, invasion, tumour
angiogenesis and drug resistance [4–13].
Alternative splicing, which is often dysregulated in
cancer, can produce various isoforms of genes with dif-
ferential properties and therefore diverse effects on can-
cer progression [14, 15]. For the MUC4 gene, 24 distinct
splice transcripts have been isolated from various tissue
samples as well as cell lines, named from sv0 (the full-
length MUC4) to sv21-MUC4, MUC4/X, and MUC4/Y
[16]. Splice variants of MUC4 are present in pancreatic
intraepithelial neoplasia and PC but not in the normal
pancreas or in chronic pancreatitis [17–21]. Thus, ex-
ploring the function of MUC4 splice variants at the pro-
tein level may help us to determine their potential
functions in pancreatic carcinomas.
MUC4/Y, a MUC4 splice variant, lacks the fragment
translated from exon 2 (encodes the tandem repeat do-
main), including the NIDO, AMOP, vWD, and EGF-like
domains, the trans-membrane domain (TM), and the
cytoplasmic tail [15, 16]. MUC4/Y is named by analogy
with MUC1/Y. Compared with MUC1, MUC1/Y lacks the
randomly repeated amino acids. As a well-established
transcript form of MUC1, MUC1/Y has important func-
tions in tumour initiation and progression [22–24]. We
have reported that MUC4/Y could stimulate PC cell line
proliferation, invasion and suppress apoptosis [25, 26].
The role of these domains of MUC4/Y is of interest.
The AMOP domain is a novel extracellular domain that
is found in some splice variants of MUC4. It is uncom-
mon in the genome, and it has been described in only 4
proteins so far: MUC4, SUSD2, ISM1, and ISM2. The
exact features of AMOP domain remain unknown, al-
though it has been suggested functional in cell adhesion
[27–29]. In this study, we investigated whether the dele-
tion of the AMOP domain could alter MUC4(MUC4/Y)-
mediated tumour biological processes in PC cells. We
found that the deletion of AMOP domain could reverse
the tumour angiogenesis and metastasis induced by
MUC4/Y. The underlying mechanism was the activation
of NOTCH3 downstream genes (VEGF-A, MMP-9 and
ANG-2) by AMOP domain. This mechanism could be a
potential therapeutic target of PC.
Methods
Cell culture
The human pancreatic cancer cell lines PANC-1 and
MiaPaCa-2 were purchased from the Shanghai Institutes
for Biological Sciences, Chinese Academy of Sciences.
They were maintained in DMEM containing 10 % foetal
bovine serum (FBS) (Wisent, Canada) and 1 % penicillin/
streptomycin (HyClone, Thermo, USA). Human umbilical
venous endothelial cells (HUVECs) (ATCC, USA) were
cultured in Endothelial Cell Growth Medium. All cell lines
were grown in a humidified chamber supplemented with
5 % CO2 at 37 °C.
Lentiviral production and Infection
The MUC4/Y (NM_004532.4, 167736352) and MUC4/
Y-AMOPΔ were synthesised artificially and cloned into
the pUC57 plasmid (Genscript Co., China). Lentiviral
production was achieved using the pUC57 plasmid car-
rying MUC4/Y (Shanghai SBO Medical Biotechnology
Co., China), with a three-plasmid system of pCDH-
CMV-MCS-EF1-Puro, pCD/NL-BH*DDD and pLTR-G.
The pancreatic cancer cell lines PANC-1 and MiaPaCa-
2 were infected following the manufacturer’s instruc-
tions. These cell lines were selected by 2 μg/ml bulk
puromycin-resistant culturing (Sigma, USA) for one
week. Then, MUC4/Y and MUC4/Y-AMOPΔ expres-
sion levels were analysed by real time qPCR and west-
ern blotting assays. The cells were then subjected to
additional assessments as follows.
mRNA extraction and real-time qPCR
Total RNA was extracted from cell lines using TRIzol
reagent (Life Technologies, USA), following the manu-
facturer’s protocols. After spectrophotometric quanti-
fication, 1 μg of total RNA was used for reverse
transcription (RT) in a final volume of 20 μl with the
Prime-Script RT Reagent (Takara, Japan), according to
the manufacturer’s instructions. The amounts of
cDNA used for the amplification of the target genes
were normalised to the human GAPDH gene. Real-
time qPCR was performed on a Step One Plus Real-
Time PCR System (Life Technologies, USA) using Fast
Start Universal SYBR Green Master Mix (Roche, USA).




CACAGCCT-3′; NOTCH1, forward: 5′-GAGGCGTGG
CAGACTATGC-3′, reverse: 5′-CTTGTACTCCGTCAG
CGTGA-3′; NOTCH2, forward: 5′-CAACCGCAATG
GAGGCTATG-3”; reverse: 5′-GCGAAGGCACAATCAT
CAATGTT-3′; NOTCH3, forward: 5′-TGGCGACCTCAC
TTACGACT-3′, reverse: 5′-CACTGGCAGTTATAGGTG
TTGAC-3′; NOTCH4, forward: 5′-GATGGGCTGGA
CACCTACAC-3′, reverse: 5′-CACACGCAGTGAAAGC
TACCA-3′; ANG-2, forward: 5′-CTGGGCGTTTTGTTG
TTGGTC-3′, reverse: 5′-GGTTTGGCATCATAGTGCTG
G-3′. Hes-1, forward: 5′-TGGATGCTCTGAAGAAAGA
TAGC-3′; reverse: 5′-CTCGGTACTTCCCCAGCAC-3′.
The 2-ΔΔCT method was used to calculate relative expres-
sion levels. Each real-time PCR was performed in triplicates
and independently repeated for three times.
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Western blotting
Protein from the cell extracts was resolved by electro-
phoresis and transferred to poly vinylidene difluoride
membrane (PVDF). After blocking with 5 % non-fat milk
in Tris-buffered saline, membranes were incubated with
specific antibodies at 4 °C overnight. The membrane was
then incubated with horseradish peroxidase labeled sec-
ondary antibodies. Proteins were visualized with the
Super Signal West Femto Maximum sensitivity substrate
kit (Thermo Scientific, Logan, UT). Western blots were
quantified using the software Image Pro Plus version 6.
The antibodies to ANG-2 (SC-7015) and GAPDH (SC-
365062) were purchased from Santa Cruz Biotechnology
(USA). The antibodies to MUC4/Y (MUC4) (#ab60720),
VEGF-A (#ab51745), CD31 (#ab28364) and Hes-1
(#ab71559) were bought from Abcam (USA). The se-
lected monoclonal antibody (#ab60720, Abcam, UK) is
specifically directed against amino acids 79–189 of hu-
man MUC4, which are included in the protein expressed
by the MUC4/Y target gene, including the AMOP,
NIDO, VWD, and the EGF-like domains. The antibodies
to NOTCH3 (#5276), and MMP-9 (#13667) were from
Cell Signalling Technology (USA). Pre-stained markers
(Thermo Scientific, USA) were used as internal molecu-
lar weight standards. Each blot was independently re-
peated three times.
In vitro HUVEC tube -formation assay
PANC-1 cells were cultured as described above. When the
cells reached 80 % confluence, the culture medium was
changed to DMEM without FBS. Following an additional
24 h of culturing, the supernatant was collected as condi-
tioned medium and stored at −80 °C. After thawing at 4 °C
overnight, the 50 μl Matrigel (BD, USA) was coated in a
96-well plate and then incubated at 37 °C for at least 1 h to
gel. HUVECs were suspended at a density of 2 × 105 cells/
ml in the different supernatants. The cell suspensions
(100 μl) were added to each Matrigel-coated well. DMEM
was used as the negative control. After 5–12 h, tube images
were taken using a digital camera attached to an inverted
phase-contrast microscope. The total tube length in each
well was measured and calculated using Image-Pro Plus
(IPP) software.
HUVEC proliferation assay
HUVECs were suspended at a density of 2 × 104 cells/
ml, and 100 μl cell suspensions were seeded into 96-well
plates. After 24 h, the medium was changed to condi-
tioned medium, as described above. Cell proliferation
was assessed using the Cell Counting Kit-8 (CCK8)
(Dojindo Laboratories, Japan), following the manufac-
turer’s protocol. The cells were stained at the indicated
time point with 10 μl CCK8 for 4 h at 37 °C in a CO2in-
cubator. The absorbance at 450 nm (OD value) was
measured using a micro-plate reader, and the absorbance
at 630 nm was used as a reference. The average OD
values were used to represent the total cell numbers of
each group. All tests were performed in triplicate.
HUVEC migration and invasion assays
Cell migration and invasion assays were performed using
a chamber 6.5 mm in diameter with an 8 μm pore size
(Corning, USA). The upper chambers were seeded with
1 × 104 HUVEC cells. Subsequently, the different condi-
tioned media were added to the lower chamber. For the
invasion assay, the top chamber was coated with 100 μl
of 1 mg/ml Matrigel (BD, USA). The cells were incu-
bated at 37 °C for 36 h. After incubation, the cells that
did not migrate through the pores and remained in the
upper chamber were removed by scraping the mem-
brane with a cotton swab. The migrated cells on the
lower side of the membrane were stained with 0.1 %
crystal violet (Sigma, USA) for 20 min at 37 °C, followed
by washing with PBS and photographing in 10 random
fields of view at 10× magnification. The cell numbers
were counted and expressed as the average number of
cells/field of view. Three independent experiments were
performed in each case.
PANC-1 migration and invasion assays
Cell migration and invasion assays were performed using
a chamber 6.5 mm in diameter with an 8 μm pore size
(Corning, USA). For migration assays, 5 × 104 PANC-EV,
PANC-MUC4/Y and PANC-MUC4/Y-AMOPΔ cells
were suspended separately in serum-free DMEM plated
in the top chamber of inserts. Then, 0.5 ml of 10 %
serum-containing DMEM was added to the lower cham-
ber of the well and the cells were allowed to migrate
under chemotactic drive at 37 °C for 24 h; the cells in
the upper chamber were then removed using cotton
swabs. For invasion assays, cells (5 × 104) were seeded on
Matrigel-coated membrane inserts. Cells migrating or
invading into the bottom of the membrane were stained
with 0.1 % crystal violet for 20 min at 37 °C, followed by
washing with PBS. Ten random fields from each mem-
brane were photographed and counted for statistical
analysis.
Animals
Four-week-old male nude mice (BALB/c-nu (nu/nu))
were purchased from the Shanghai Experiment Animal
Center (Chinese Academy of Sciences, China) and
housed in specific pathogen-free conditions. This study
was conducted in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory
Animals of the Ministry of Health, China. The Ethics
Committee of the First Affiliated Hospital of Nanjing
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Medical University (Permit Number: 2012-SRFA-093)
approved the protocol.
Matrigel plug assay
We conducted a Matrigel plug assay to investigate the
tumour angiogenesis properties of MUC4/Y and domain
deletion. Twenty-four male mice were randomly divided
into three groups. PANC-EV, PANC-MUC4/Y, and
PANC-MUC4/Y-AMOPΔ cells were re-suspended at 2 ×
107 cells/ml in serum-free medium. Aliquots of cells
(0.4 ml, 8 × 106 cells) were mixed with 0.4 ml Matrigel
and unilaterally injected into the flank of each mouse
(100 μl mixture/per flank). Matrigel mixed with medium
served as a negative control. The Matrigel plugs were re-
moved 15 days after implantation. Half of the plugs were
used for the measurement of haemoglobin content using
Drabkin’s reagent (Sigma, USA). The remaining part of
the plugs were fixed in 4 % formalin, embedded in paraf-
fin and used for IHC analysis.
In vivo tumour metastasis
To investigate the functional consequences of the
MUC4/Y and MUC4/Y-AMOP domain on the meta-
static properties of PC cells, orthotopic implantation was
carried out. Twenty-four mice were randomly divided
into three groups (PANC-EV, PANC-MUC4/Y, PANC-
MUC4/Y-AMOPΔ). The PANC-1 derived cells were har-
vested from sub-confluent cultures and re-suspended in
PBS at a concentration of 2 × 106 cells/100 μl. Single-cell
suspensions of >95 % viability were used for the assays.
The animals were anesthetised with intra-peritoneal
0.1 % pentobarbital sodium. All surgical procedures were
performed under sterile conditions. Two million cells
suspended in 100 μl of PBS were injected into the pan-
creas by a 30-gauge needle. The animals were monitored
every two days. To determine tumour metastasis, mice
were euthanised by CO2 asphyxiation and autopsied
45 days after the implantation of the tumour cells. Re-
gional and distant lymph nodes, liver, lung and other or-
gans suspected of harbouring metastases were routinely
formalin-fixed, embedded, sectioned, and stained with
hematoxylin and eosin using standard techniques for
microscopic examination.
Immunohistochemistry (IHC)
All specimens were fixed in 4 % formalin and embedded
in paraffin before IHC analysis. All procedures with ref-
erence to our previous reports [15]. The tumour slides
were examined in a blinded manner. Five fields were se-
lected for examination, and the percentage of positive
tumour cells and cell-staining intensity were determined.
Micro-vessel density (MVD) was counted by CD31
staining. Five areas with the highest MVD were chosen
for counting under 200× magnification. The average
number of vessels in the five areas was considered as the
MVD level of the case. Any brown-staining endothelial
cells or endothelial cell clusters that were clearly separ-
ate from adjacent micro-vessels, tumour cells, and other
connective tissue elements, were recorded as a single
countable micro-vessel. Even those distinct clusters of
the stained endothelial cells that might come from the
same vessel snaking its way in and out of the section
were considered as separate micro-vessels.
VEGF-A assay
Because VEGFA and MMP9 are secreted factors, they
mainly work through paracrine. So we used the com-
mercial kits to test the activity of VEGFA and MMP9 in
the conditioned medium of different groups. The
PANC-EV, PANC-MUC4/Y or PANC-MUC4/Y-AMOPΔ
cells were seeded in six-well plates (1.5 × 105 per well),
and incubated at 37 °C. After 24 h, the cell culture
supernatant was harvested and cell counts were per-
formed after trypsinisation. After collection, the medium
was spun at 800 × g for 3 min at 4 °C to remove cell deb-
ris. The supernatant was either frozen at −80 °C for later
activity assays or assayed immediately using commer-
cially available ELISA kits (R&D systems, USA).
MMP-9 activity assay
The PANC-EV, PANC-MUC4/Y or PANC-MUC4/Y-
AMOPΔ cells were seeded in six-well plates and incu-
bated at 37 °C. After 24 h, the medium was removed
and the cells were washed with serum-free medium. The
cells were then incubated in serum-free medium for
24 h. MMP-9 activity in the medium was detected using
the Fluorokine E Human MMP-9 Activity Assay kit
(R&D systems, USA), according to the manufacturer’s
protocol.
Statistical analysis
Statistical analysis was performed using the SPSS
(Statistical Package for the Social Sciences) software
package (Version 18.0). Quantitative data are pre-
sented as the mean ± SD. Differences in the mean
values of two samples were analysed by Student’s t-
test. The Kaplan-Meier method was used to deter-
mine the survival distributions and overall survival
rates, and the significance of differences between survival
rates was calculated by the log-rank test. P < 0.05 was con-
sidered significant.
Results
Construction of MUC4/Y and MUC4/Y-AMOPΔ
overexpression cell lines
To investigate the possible role of the MUC4/Y-AMOP
domain, we constructed MUC4/Y and MUC4/Y-AMOPΔ
lentivirus vectors and infected the PANC-1 cells. The
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structure organization of MUC4, the MUC4/Y, and the
truncated protein (MUC4/Y-AMOPΔ), were shown in
Fig. 1a. The exact “aa” position for the AMOP domain
that was deleted was shown in Additional file 1: Table
S1. PANC-1 cells without MUC4/Y (MUC4) expression,
as we previously reported [16], were chosen to establish
the stable cells lines. Real-time PCR and western blot-
ting assays were used to confirm the expression of
MUC4/Y (PANC-MUC4/Y) or the MUC4/Y without the
AMOP domain (PANC-MUC4/Y-AMOPΔ) at mRNA
(Fig. 1b) and protein levels (Fig. 1b). The MUC4/Y-
AMOP△ protein (~110 KD) was smaller than MUC4/
Y(~120KD), perhaps because of the AMOP domain de-
letion (Fig. 1c). Cell immunofluorescence assay showed
that the MUC4/Y and the truncated protein (MUC4/Y-
AMOPΔ) could anchor on the cyto-membrane and cyto-
plasm. It clearly pointed out that the deletion of the
AMOP domain would not change the localization of the
MUC4/Y protein (Fig. 1d).
For the reproducibility of the results, we chose one more
PC cell line (MiaPaCa-2, MIA) to repeat the above experi-
ments. We found the similar phenomenon as we observed
in PANC-1 cell line (Additional file 1: Figure S1a, b and c).
MUC4/Y-AMOP domain regulates the processes of tumour
angiogenesis in vitro
To confirm the role of the MUC4/Y-AMOP domain in
tumour angiogenesis, the HUVEC cells tube formation,
migration, invasion and proliferation assays were per-
formed in vitro.
We used cell migration and matrigel invasion assays to
investigate the effects of the MUC4/Y-AMOP domain in
HUVEC migration and invasion. The number of HUVEC
that migrated to the lower surface of the insert chamber
Fig. 1 MUC4/Y and MUC4/Y-AMOP domain-deletion constructs and their stable expression in PANC-1 cells. a The structure diagram of the MUC4,
MUC4/Y and MUC4/Y-AMOP△. Different domains present in MUC4 protein are the central large tandem repeat domain, NIDO, AMOP, vWD, and 3
carboxyl-terminal located EGF domains. b MUC4/Y expression was analysed by real-time PCR in different PANC-1 derived sub-lines. GAPDH was
used as an internal control. c Western blotting was conducted to analyse the protein level of MUC4/Y in different groups. GAPDH was probed as an
internal control. d Cell confocal immunofluorescence assay showed that the MUC4/Y and the truncated protein (MUC4/Y-AMOPΔ) could anchor on
the cytomembrane and cytoplasm.**P < 0.01
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was increased by the conditioned medium from MUC4/Y
group cells compared with MUC4/Y-AMOPΔ and control
(EV) groups both in cell migration and matrigel invasion
assays (Fig. 2a, Additional file 1: Figure S2A).
We also used the CCK8 assay to assess the effects of
HUVEC proliferation in the conditioned medium of dif-
ferent groups. The proliferation of HUVEC in the condi-
tioned medium of the MUC4/Y overexpression group
was increased compared with the other two groups
(Fig. 2b, Additional file 1: Figure S2B).
Next, tube-formation assays with HUVEC were per-
formed using different conditioned medium (EV, MUC4/
Y, and MUC4/Y-AMOPΔ). Consistent with the results
above, the deletion of AMOP domain could decrease the
tube-forming capacity of HUVEC cells that MUC4/Y en-
hanced (Fig. 2c, Additional file 1: Figure S2C).
Fig. 2 Effects of the MUC4/Y-AMOP domain-deletion on the migration and invasion of PANC-1 derived sub-lines and the conditioned medium
on the tube formation, proliferation, migration, and invasion of HUVEC. a Trans-well migration and Matrigel invasion assays of HUVEC were performed
in the conditioned medium of different groups. b CCK8 assay. The OD value was used to assess the proliferation of HUVEC in the conditioned medium
of different groups. c Tube formation assays of HUVEC. The area of network was calculated with Image Pro Plus 6.0. d Trans-well migration and Matrigel
invasion assays of PANC-1 derived sub-lines. The number of cells that migrate or invade to the lower surface of the inserts chamber were stained and
photographed. *P < 0.05, **P < 0.01
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MUC4/Y-AMOP domain promotes the motility and
invasive ability of PC cells
The trans-well assay was used to determine the role of the
MUC4/Y-AMOP domain in PC cell migration and inva-
sion. The number of cells that migrate or invade to the
lower surface of the insert chamber was greater in the
MUC4/Y overexpressed cells than the cells without
MUC4 expression or cells with MUC4/Y-AMOPΔ(Fig. 2d,
Additional file 1: Figure S2D).
MUC4/Y-AMOP domain facilitates tumour angiogenesis in
vivo
To further study the effects of the MUC4/Y-AMOP do-
main on tumour angiogenesis in PC, in vivo experiments
were performed using the Matrigel plug assay. PANC-EV,
PANC-MUC4/Y and PANC-MUC4-AMOPΔ cells were
suspended in a Matrigel/DMEM mixture and subcutane-
ously injected into mice (Fig. 3a). Consistent with the previ-
ous results, the PANC-MUC4/Y cells formed more vessels
(MVD) compared with the PANC-MUC4/Y-AMOPΔ and
PANC-EV groups (Fig. 3b and c). Furthermore, the
haemoglobin concentration was measured following Matri-
gel dissolution to assess the number of functional vessels.
The PANC-MUC4/Y group also showed significantly
higher levels of haemoglobin (Fig. 3d).
MUC4/Y-AMOP domain is an independent predictor of
unfavourable outcome of the tumour-bearing nude mice
PANC-1-derived cells were orthotopically injected into
the head of the pancreas on day 0 as described above. The
mice were randomised into three groups (15 mice/group):
control group (PANC-EV), MUC4/Y overexpression
group (PANC-MUC4/Y), and MUC4/Y without AMOP-
domain overexpression group (PANC-MUC4/Y-AMO△).
The endpoint of this study was the death of the mice. The
efficacy study was terminated on day 147 (21 weeks) post-
tumour cell injection. As shown in Fig. 3e, the Kaplan-
Meier survival curves showed that mice injected with
PANC-MUC4/Y cells had shorter survival time than those
injected with PANC-EV or PANC-MUC4/Y-AMOPΔ. The
control group had a median survival of 130 days, which
was much longer than the 76 days in MUC4/Y
Fig. 3 Matrigel plug assay and the correlation between MUC4/Y-AMOP domain and mouse survival. a Cells were suspended in Matrigel and
DMEM and subcutaneously into the flanks of mice (n = 8). After 15 days, the Matrigel plugs were removed and photographed. Representative
Matrigel plugs from the PANC-EV, PANC-MUC4/Y, and PANC-MUC4/Y-AMOP△groups are shown. b The relative amount of angiogenesis was analysed
based on the RBC haemoglobin level, determined using the Drabkin method. The relative haemoglobin content is the haemoglobin level (mg) divided by
the final volume of each plug. c CD31 immunohistochemistry was performed on the Matrigel plugs from the PANC-EV, PANC-MUC4/Y, and PANC-MUC4/
Y-AMOP△groups. d Microvessel density of CD31 immunohistochemistry. Each slide was evaluated with five fields, and the data were analysed as the mean
vessel number of these five fields. e Kaplan-Meier survival curves in 45 mice with PANC-1 derived sub-lines orthotopically implanted. The p values were
calculated by the log-rank test (Table 1)
Tang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:91 Page 7 of 13
overexpression group. The median survival time of the
PANC-MUC4/Y-AMOP△ group was not significantly
different compared with the control group (Fig. 3e and
Table 1).
The MUC4/Y-AMOP domain promotes metastasis of
PANC-1 cells in vivo
We confirmed the metastatic effect of the MUC4/Y-
AMOP domain in vivo using orthotopic injection with
infected cells into nude mice. The overall tumour inci-
dence of pancreas among the three groups (8mice/
group, 100 %) has no significant difference. However,
there were higher incidences of metastasis at different
sites in the MUC4/Y overexpressed group compared
with the other two groups, including liver, mesenteric,
lung and malignant ascites, suggesting that the AMOP
domain had an important role in the metastasis. The in-
cidence of metastasis in spleen was same (8mice, 100 %)
in the three groups, indicating that MUC4/Y might have
no impact on the local invasion (Table 2). We found no
significant difference of metastasis in peritoneum, possi-
bility due to the limited number of sample. We con-
firmed by visual and histological inspection. The arrows
pointed to the metastatic nodes (Fig. 4a and b)
The MUC4/Y-AMOP domain is involved in MUC4/Y up-
regulation of the expression of NOTCH3
To identify the pathways activated by the MUC4/Y-AMOP
domain in PC, which might reveal the mechanism by which
the MUC4/Y-AMOP domain enhanced tumour angiogen-
esis and metastasis of PC, the Real-Time qPCR and
Western Blotting assays were conducted. We found that
NOTCH3 mRNA (Additional file 1: Figure S3C) and pro-
tein levels (Fig. 5a) were dramatically increased in the
MUC4/Y overexpressed cells. There was no obvious change
of the other NOTCH receptors (NOTCH1, NOTCH2, or
NOTCH4) (Additional file 1: Figure S3A, B, D). In addition,
we also found that the expression of activated NOTCH3
(N3ICD), and its downstream target gene, Hes-1, were un-
regulated in MUC4/Y overexpression cells. However, the
overexpression of MUC4/Y-AMOPΔ did not affect the ex-
pression of NOTCH3 and its target gene, compared with
the control cells (Fig. 5a, Additional file 1: Figure S3E). IHF
analysis was carried out on the frozen pancreatic tumour
tissue sections to confirm the expression of MUC4/Y and
NOTCH3. In this assay, we found that the expression of
NOTCH3 was dramatically increased in the MUC4/Y
group compared with the other two groups, similar to our
previous results (Fig. 5b).
The MUC4/Y-AMOP domain has an important role in
MUC4/Y, increasing the expression of VEGF-A, ANG-2 and
MMP-9
It has been reported that VEGF and MMP-9 expression
reduced in the stable MUC4 knockdown pancreatic can-
cer cell line [4, 30, 31]. The NOTCH signalling pathway
may also regulate VEGF and MMP-9, which has been
well documented in PC cell lines [32]. Therefore, we in-
vestigated whether VEGF-A and MMP-9 were up-
regulated by MUC4/Y and the possible role of the
AMOP domain in it. Western blotting was conducted to
explore the expression of VEGF-A and MMP-9. We
found that the protein levels of VEGF-A and MMP-9
were dramatically increased in the MUC4/Y overexpres-
sion group compared with the MUC4/Y-AMOPΔ and
control groups (Fig. 5c). Next, we examined the activity
of VEGF-A and MMP-9. We found a marked increase in
the expression of VEGF-A and MMP-9 in PANC-
MUC4/Y cells than the other two groups (Fig. 5d and e).
It has been reported that the NOTCH pathway affects
angiopoietin 2 (ANG-2) [33]. Therefore, we investigated
whether ANG-2 expression was regulated via NOTCH3
mediated by MUC4/Y and its AMOP domain. Real-time
qPCR and western blotting were used to explore the ex-
pression of ANG-2. We found that MUC4/Y could in-
crease both mRNA and protein levels of ANG-2,
whereas no change was found in the MUC4/Y-AMOPΔ
group (Fig. 5c and f).
To confirm that the MUC4/Y-AMOP domain up-
regulates the expression of VEGF-A, MMP-9, and ANG-
2 via NOTCH3 signalling, we added an experimental
group as following: PANC-MUC4/Y + DAPT (5umol/L,
48 h; γ-secretase inhibitors (GSI) can inhibit the proteo-
lytic processing of NOTCH receptors by γ-secretase,
which is essential for NOTCH activation) [34]. We
found that DAPT could counteract the effects: the in-
creased expression or activities of VEGF-A, MMP-9, and
ANG-2 (Fig. 5c-f), which could lead to angiogenesis and
metastasis of PC cells.
Discussion
The MUC4 protein is a large transmembrane type I
glycoprotein that contains several important functional
domains. However, because of the technical restrictions
in cloning and modifying the large cDNA of MUC4, dir-
ect experimental proof for the role of individual MUC4
extracellular domain in cancer development and pro-
gression has been difficult to obtain.
Table 1 Log Rank (Mantel-Cox)——Pairwise Comparisons
Group PANC-EV PANC-MUC4/Y PANC-MUC4/
Y-AMOP△






The endpoint of the assay is the death of the mice. **p<0.01
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MUC4/Y, a transcript variant of MUC4, lacks the tran-
scription from exon 2 (the tandem repeat domains)
compared with the full length MUC4 [16]. Thus, the val-
idated functions of this transcript variant may help us to
understand the potential functions of MUC4 in PC de-
velopment and progression. Because MUC4/Y lacks the
large fragment of exon 2, we can study the functions of
MUC4/Y and the domains it contains (NIDO, AMOP,
vWD, EGF-like) using the overexpression lentivirus
system.
Some previous studies showed that MUC4 and HER2
interact physically and transduce intracellular signals to
promote a series of biological processes in PC cells [34, 35].
In this study, we conducted the western blot assay again to
check the expression of total-ErbB2/phosphor-ErbB2. We
found that the expression of total-ErbB2 and phosphor-
ErbB2 were increased in PANC-MUC4/Y group, while no
obvious change of them was found when the AMOP do-
main was deleted. So, we concluded that MUC4/Y might
activate the ErbB2, while not through the AMOP domain
(Additional file 1: Figure S3F).
Other laboratories reported that the MUC4-NIDO do-
main could contribute to the MUC4-mediated metasta-
sis of PC cells by expressing the engineered MUC4
(mini MUC4) and MUC4 without the NIDO-domains.
In these studies, they showed that MUC4-NIDO
domain-mediated metastasis might be partly due to its
interaction with the endogenous fibulin-2 protein [36].
Table 2 The incidence rate of the tumour at different sites
Group Organ Malignant
Ascites (%)Pancreas Liver Spleen Peritoneum Mesentery Lung
PANC-MUC4/Y vs PANC-EV 8/8 vs 8/8 8/8 vs 1/8 8/8 vs 8/8 4/8 vs 1/8 4/8 vs 0/8 5/8 vs 0/8 4/8 vs 0/8
P > 0.05 P < 0.01 P > 0.05 P > 0.05 P < 0.05 P < 0.05 P < 0.05
PANC-MUC4/Y vs PANC-MUC4/Y-AMOPΔ 8/8 vs 8/8 8/8 vs 2/8 8/8 vs 8/8 4/8 vs 1/8 4/8 vs 0/8 5/8 vs 0/8 4/8 vs 0/8
P > 0.05 P < 0.01 P > 0.05 P > 0.05 P < 0.05 P < 0.05 P < 0.05
PANC-EV vs PANC-MUC4/Y-AMOPΔ 8/8 vs 8/8 1/8 vs 2/8 8/8 vs 8/8 1/8 vs 1/8 0/8 vs 0/8 0/8 vs 0/8 0/8 vs 0/8
P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
Fig. 4 Macroscopic and microscopic examination of organs with metastatic lesions and orthotopic pancreatic tumours. 24 mice were randomly
divided into three groups (PANC-EV, PANC-MUC4/Y, PANC-MUC4/Y-AMOPΔ). The different groups PANC-1 derived cells (2 × 106 cells/
100 μl) were orthotopic implanted into pancreas. Forties five dayed later, mice were euthanised by CO2 asphyxiation and autopsied (a)
The macroscopic examination of organs with metastatic lesions (includes liver, spleen, lung, peritoneum, and mesentery), malignant ascites
and orthotopic pancreatic tumours. The arrows pointed the metastatic nodes. b H&E staining was used to the histological change. Normal
(N) and tumour lesions (T) in different organs are separated as indicated
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Komatsu et al. showed that overexpression of Muc4 (rat
Muc4) or MUC4 hindered integrin-mediated cell-cell
and cell-ECM adhesion in vitro because of the large size
of MUC4 [37, 38]. In order to avoid changing the spatial
structure, we focused on MUC4/Y, a natural transcript
variant of MUC4, lacks fragment from exon 2 (~120
KD), from another point of view: signal transduction, in
the current study. The results of real-time qPCR and
western blotting experiments showed that MUC4/Y
could activate NOTCH3 signalling, and the loss of the
MUC4/Y-AMOP domain decreased the activity. The
NOTCH signalling is abnormally activated in many hu-
man malignancies, including pancreatic cancer [39–43].
It is known to play critical roles in the processes of
tumour cell angiogenesis, proliferation, invasion, and
metastasis [32, 40, 44–47]. Therefore, MUC4/Y-AMOP
domain-promoted tumour angiogenesis and metastasis
may be partly due to the activation of NOTCH3.
Many studies have documented that VEGF is a critical
mediator of angiogenesis and metastasis [48–52]. Here,
we showed that MUC4/Y-overexpression increased
VEGF-A protein expression. We also found a marked in-
crease in the secreted form of VEGF-A in the conditioned
medium of MUC4/Y-overexpressed cells. However, the
loss of the AMOP domain reduced the expression of
VEGF-A induced by MUC4/Y.
Another important class of molecules involved in
tumour metastasis and angiogenesis are the MMPs. It is
known that MMPs are critically involved in the pro-
cesses of tumour cell invasion and metastasis and that
MMP-9 is directly associated with angiogenesis and
metastatic processes [4, 32, 46, 53, 54]. In this study, we
showed that overexpression of MUC4/Y increased
MMP-9 protein levels and activity.
Apart from VEGF and MMPs, ANG-2 plays crucial role
in tumour angiogenesis [55–58]. Although the role and
Fig. 5 Mechanisms involved in MUC4/Y-AMOP domain regulating angiogenesis and metastasis. a Effects of MUC4/Y and its AMOP domain on
the NOTCH3 signalling pathway (NOTCH3, N3ICD, HES-1) were assayed by western blotting. GAPDH was used as the internal control. b Immunofluores-
cence was used to assess the NOTCH3 and MUC4(MUC/Y) protein level. c Western blotting assays were conducted to analyse the protein level of VEGF-A,
MMP-9, ANG-2 and N3ICD in different groups. GAPDH was used as the internal control. d The secreted level of VEGF-A in conditioned medium was de-
tected by an ELISA kit assay. e The activity of MMP-9 in different groups was detected by using a Fluorokine E Human MMP-9 Activity Assay kit assay. f The
mRNA expression of ANG-2 in different groups. DAPT: γ-secretase inhibitors (GSI) can inhibit the proteolytic processing of Notch receptors by γ-secretase,
which is essential for Notch activation. **P< 0.01
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mechanism of ANG-2 in tumour angiogenesis has not
been fully clarified, experimental studies have demon-
strated a close relationship of VEGF and ANG-2 functions
in angiogenesis. ANG-2 promotes vessel sprouting in the
presence of abundant VEGF, whereas ANG-2 contributed
to vessel regression in the absence of VEGF [59, 60].
There are no reports of a connection between ANG-2 and
MUC4/Y (MUC4) yet. However, it has been reported that
ANG-2 is involved in NOTCH signalling. In this study, we
found that MUC4/Y could increase both mRNA and pro-
tein levels of ANG-2, whereas no change was found in the
MUC4/Y-AMOPΔ group.
Finally, we found that DAPT could counteract the in-
creased expression or activities of Hes-1, VEGF-A, MMP-9,
and ANG-2 caused by MUC4/Y overexpression. This result
demonstrated that NOTCH3 signalling was the key mech-
anism underlying these complex phenomena.
Based on our results, we speculate one possible mech-
anism that the MUC4/Y-AMOP domain induces invasion
and angiogenesis by activating NOTCH3 to up-regulate
the downstream functional genes, such as VEGF-A,
MMP-9, and ANG-2. In addition, taking the membrane
location into account, we presume that the MUC4/Y-
AMOP domain may be the key region involved in MUC4/
Y binding to NOTCH3. This mechanism may be import-
ant in various biological processes mediated by MUC4. In
subsequent experiments, we will attempt to validate our
ideas and further ascertain the precise molecular inter-
action between the MUC4/Y-AMOP domain and
NOTCH3. When the functions of MUC4 (MUC4/Y) and
AMOP domain in pancreatic cancer are clarified, we
could design some specific sequence such as aptamer/
siRNA to silence them, in order to reduce, or even block
the malignant biological behavior of pancreatic cancer.
Furthermore, we are the first to use a transcript vari-
ant model to study the specific domains of a high mo-
lecular weight membrane protein that is difficult to
overexpress. In the future, the method we used to inves-
tigate the AMOP domain can be a model for studying
other high molecular weight membrane proteins. The
data in this study are also consistent with the hypothesis
that MUC4 is a multifunctional target for the treatment
of PC.
Conclusions
In conclusion, the present study provides evidence that
AMOP domain plays the key role in MUC4/Y(MUC4)-me-
diated tumour angiogenesis and metastasis of PC cells
partly through the NOTCH3 signalling and its downstream
target genes: VEGF-A, MMP-9 and ANG-2. This mechan-
ism could be the potential therapeutic target of PC. Fur-
thermore, the method we used to investigate the AMOP
domain could be a model for studying other high molecular
weight membrane proteins.
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